IDEXX Expands Catalyst Platform into Cardiac Disease with First and Only Dual-Species Point-of-Care NT-proBNP Test
Idexx Laboratories (Nasdaq: IDXX) announced the Catalyst proBNP Test, an in-clinic NT-proBNP assay for both cats and dogs, integrated with its Catalyst point-of-care platform and VetConnect PLUS. The company says it targets a cardiac biomarker used for screening, diagnosis, and monitoring, with availability in North America starting October 2026.
How this was made
The 30-second read
Why it matters
The announcement adds a new quantitative cardiac biomarker test to IDEXX’s in-clinic and connected diagnostic ecosystem, aiming to reduce delays and referrals by delivering results during the visit.
Market read
Traders may view this as a strategic product expansion into veterinary cardiac diagnostics, but the lack of near-term financial impact details limits immediate earnings sensitivity.
What to watch
Adoption may depend on workflow fit, clinician trust in point-of-care NT-proBNP interpretation, and whether cardiology referral patterns shift enough to drive measurable test volume.
Background
IDEXX is expanding its Catalyst connected point-of-care platform with a new NT-proBNP test for cardiac assessment in cats and dogs.
Ticker impact
IDEXX launched the Catalyst proBNP Test, a dual-species in-clinic NT-proBNP assay for cats and dogs, expanding its point-of-care cardiac menu.
Near-term sentiment could be mildly positive, with follow-through depending on adoption and any incremental revenue commentary in future updates.
This is a concrete product launch with clear commercialization timing (North America starting October 2026) and distribution via an 80,000-analyzer installed base, but the article provides no unit economics, pricing, or early traction data.
Market effects
Strengthens the competitive push toward in-clinic quantitative biomarker testing in veterinary diagnostics, which could pressure peers to broaden point-of-care cardiac offerings.
North America commercialization begins October 2026, with international rollout later, creating a staged adoption curve.
If widely adopted, could expand the addressable market for veterinary cardiac diagnostics globally, aligning with the company’s stated ~$4B opportunity estimate.
Counterpoint
Without pricing, reimbursement dynamics, or early adoption metrics, the market may treat this as incremental rather than a material near-term revenue driver.
Key entities
- companyIDEXX Laboratories, Inc.
Developer of the Catalyst platform and the newly launched Catalyst proBNP Test for cats and dogs.
- productCatalyst™ proBNP Test
Dual-species, in-clinic NT-proBNP point-of-care assay for cardiac screening, diagnosis support, and monitoring.
- softwareVetConnect™ PLUS
Connected platform where Catalyst proBNP results appear with built-in guidance for interpretation.
